What is the recommended treatment for a pregnant or non-pregnant woman with bacterial vaginosis?

Treatment of Bacterial Vaginosis

Non-Pregnant Women with Symptomatic BV

All symptomatic non-pregnant women with bacterial vaginosis should be treated with one of three first-line regimens: metronidazole 500 mg orally twice daily for 7 days, metronidazole gel 0.75% intravaginally once daily for 5 days, or clindamycin cream 2% intravaginally once daily for 7 days. 1

First-Line Treatment Options

• Metronidazole 500 mg orally twice daily for 7 days achieves a 95% cure rate and is the most effective oral regimen 1
• Metronidazole gel 0.75% intravaginally once daily for 5 days provides equivalent efficacy with local application 1
• Clindamycin cream 2% intravaginally at bedtime for 7 days serves as an alternative first-line option 1

Alternative Regimens

• Metronidazole 2g orally as a single dose has lower efficacy at 84% compared to the 7-day regimen but may be used when adherence is a concern 1
• Clindamycin 300 mg orally twice daily for 7 days is another alternative option 1
• Tinidazole 2g orally once daily for 2 days or 1g orally once daily for 5 days demonstrated therapeutic cure rates of 27.4% and 36.8% respectively in controlled trials (compared to 5.1% for placebo) 2

Critical Safety Considerations

• Patients taking metronidazole or tinidazole must avoid alcohol during treatment and for 24 hours (metronidazole) or 3 days (tinidazole) afterward due to potential disulfiram-like reactions 1, 2
• Clindamycin cream is oil-based and weakens latex condoms and diaphragms during use and for 5 days after completion 1
• All medications should be taken with food to minimize gastrointestinal side effects 2

Partner Management

• Routine treatment of male sexual partners is not recommended as it has not been shown to reduce BV recurrence rates 3, 1

---

Pregnant Women with Symptomatic BV

All symptomatic pregnant women with bacterial vaginosis should be treated with oral metronidazole 250 mg three times daily for 7 days or oral clindamycin 300 mg twice daily for 7 days. 4

Why Systemic Therapy is Preferred in Pregnancy

• BV during pregnancy is associated with serious adverse outcomes including premature rupture of membranes, preterm labor, preterm birth, chorioamnionitis, and postpartum endometritis 4
• Systemic (oral) therapy is preferred over topical therapy to treat potential subclinical upper tract infection 5

Recommended Treatment Regimens

• Metronidazole 250 mg orally three times daily for 7 days is the first-line systemic therapy recommended by the American College of Obstetricians and Gynecologists 4
• Clindamycin 300 mg orally twice daily for 7 days serves as an alternative first-line systemic option 4

Follow-Up in Pregnancy

• A follow-up evaluation 1 month after treatment completion is recommended to verify cure, given the potential for adverse pregnancy outcomes if treatment fails 1, 4

---

Asymptomatic BV in Non-Pregnant Women

Asymptomatic BV in non-pregnant women generally does not require treatment except before surgical abortion or hysterectomy. 1

When to Treat Asymptomatic BV

• Before surgical abortion procedures, treatment substantially reduces post-abortion pelvic inflammatory disease risk 1
• Before hysterectomy and other invasive gynecological procedures, treatment reduces postoperative infectious complications by 10-75% 3, 1
• BV has been associated with endometritis, PID, and vaginal cuff cellulitis after procedures including endometrial biopsy, IUD placement, and uterine curettage 1

Treatment Regimens When Indicated

Use the same regimens as for symptomatic non-pregnant women (metronidazole 500 mg orally twice daily for 7 days, metronidazole gel 0.75% intravaginally once daily for 5 days, or clindamycin cream 2% intravaginally for 7 days) 1

---

Asymptomatic BV in Pregnant Women

Routine screening and treatment of asymptomatic bacterial vaginosis is NOT recommended in average-risk pregnant women, but should be considered in high-risk women with a history of prior preterm delivery. 1

Risk Stratification Determines Management

• The U.S. Preventive Services Task Force gives a D recommendation (advising against) routine screening for asymptomatic BV in average-risk pregnant women, as it does not improve outcomes 1
• High-risk pregnant women (those with history of preterm delivery) may be evaluated for treatment, as three of four randomized controlled trials showed reduced preterm delivery rates with treatment 1, 4

Screening and Treatment Timing

• Optimal screening time for high-risk women is in the second trimester (13-24 weeks of pregnancy) 1
• If treatment is indicated, use metronidazole 250 mg orally three times daily for 7 days or clindamycin 300 mg orally twice daily for 7 days 4
• Follow-up evaluation one month after treatment is recommended in pregnant women to verify cure 1

---

Recurrent BV

For recurrent BV, use an extended course of metronidazole 500 mg orally twice daily for 10-14 days; if ineffective, switch to metronidazole gel 0.75% for 10 days followed by twice weekly maintenance for 3-6 months. 6

Why Recurrence is Common

• 50-80% of women experience BV recurrence within one year of completing antibiotic treatment 7, 6
• Recurrence may be due to biofilm persistence, antibiotic resistance, or failure to reestablish lactobacillus-dominated flora 6, 8

Treatment Approach

• Extended metronidazole therapy (10-14 days) is the first approach for recurrent disease 6
• Suppressive maintenance therapy with metronidazole gel twice weekly for 3-6 months can be used if extended therapy fails 6